Stockreport

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncolog...

TransCode Therapeutics, Inc.  (RNAZ) 
PDF Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviproti [Read more]